Nabriva Corporate
Go to...
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us
  • News & Publications
  • Careers
  • Contact Us
Nabriva Corporate
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us

Nabriva Sitemap

Home / Nabriva Sitemap

Sitemap

  • Home
  • About Nabriva
    • Meet the Team
  • Pipeline & Research
    • Pleuromutilins Research
    • Medical Education Grants
    • Investigator-Initiated Research Grants
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • Careers
  • Contact Us

Nabriva Response to COVID-19

Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic.  Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics.  XenletaTM (lefamulin) may be an alternative regimen for patients in need.  Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors.  Learn more at www.XENLETA.com.

Again, to all the medical professionals, please be safe, take care of yourself and stay well.

Best,
Ted Schroeder
CEO, Nabriva Therapeutics

Continue to site

Nabriva logo
  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap
Nabriva logo

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland